"Gamma Medica is committed to making MBI a more widely used tool in the battle against breast cancer," said Jim Calandra, president and chief executive officer of Gamma Medica. "We are pleased to have been recognized by Frost & Sullivan for our efforts and are excited to drive breast cancer diagnosis technology forward with highly advanced, patient-friendly and cost-effective tools."
Gamma Medica has made its products commercially available throughout the United States, as well as in certain parts of Europe, and hopes to expand to other regions of the world. By utilizing innovative technologies and effective growth strategies, Gamma Medica has ensured a superior competitive position for itself in the global breast imaging systems market.
Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About Gamma Medica
Gamma Medica, Inc. is dedicated to the development of advanced digital imaging technologies that address the growing importance of overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company designs, builds and services the LumaGEM® Digital MBI system, the first commercially available, FDA-cleared planar, dual head, fully solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology for molecular breast imaging. For more information, visit www.gammamedica.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Back to HCB News
